Summary
- Profile Type
- Technology request
- POD Reference
- TRGR20260710001
- Term of Validity
- 13 July 2026 - 13 July 2027
- Company's Country
- Greece
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
General information
- Short Summary
- A Greek SME developing a patent-pending dermocosmetic delivery system for sensitive active ingredients such as NAD+ is seeking specialised laboratories or contract research organisations with expertise in skin penetration, dermal absorption and bioanalytical testing. The partner should be able to conduct an in vitro percutaneous penetration study using reconstructed human epidermis. Cooperation is sought under a commercial agreement with technical assistance.
- Full Description
-
A Greek SME develops and markets handmade cosmetic skincare products, including serums, eye creams, sunscreen products, cream bases and active ingredient-based formulations. The company’s approach focuses on personalised skincare solutions adapted to the specific needs of each skin type, avoiding unnecessarily complex skincare routines. Building on this activity, the company is developing an advanced, patent-pending dermocosmetic delivery system for topical cosmetic applications.
The system is designed to support the stabilisation and synchronised, multi-phase release of sensitive active ingredients, including nicotinamide adenine dinucleotide, commonly known as NAD+, and targeted signalling peptides. The product has reached a stage where external laboratory testing is needed to assess the skin penetration and distribution profile of NAD+ as a selected marker under controlled in vitro conditions.
The requested study should evaluate the penetration potential of NAD+ using a reconstructed human epidermis model under physiological conditions and provide quantitative evidence on the behaviour of the marker after topical application. The study is expected to result in a comprehensive technical report, including data analysis and statistical evaluation.
The company is seeking a specialised skin penetration testing laboratory, dermal absorption laboratory, bioanalytical laboratory, contract research organisation, research institute or university laboratory able to provide the requested testing service under a commercial agreement with technical assistance. The company is expecting the final results to be delivered by 31 October 2026. - Advantages and Innovations
- The company is developing an advanced, patent-pending transdermal delivery system designed for dermocosmetic applications. The system focuses on the stabilisation and controlled release of sensitive active ingredients, such as NAD+, which are difficult to incorporate effectively into topical formulations due to their sensitivity and limited skin penetration potential. Its innovative character lies in the formulation architecture, which aims to improve the protection, delivery and targeted release of active ingredients through the skin, supporting the development of more advanced and functional dermocosmetic products.
- Technical Specification or Expertise Sought
-
The company is seeking a specialised skin penetration testing laboratory, dermal absorption laboratory, bioanalytical laboratory, contract research organisation, research institute or university laboratory with proven experience in in vitro percutaneous penetration, dermal absorption or transdermal delivery studies.
The partner should have the necessary equipment, validated methods and scientific expertise to work with reconstructed human epidermis models and topical cosmetic or dermocosmetic formulations under physiological conditions. Experience with Franz diffusion cells or equivalent in vitro penetration testing systems would be highly relevant.
The partner should also have the analytical capacity to quantify NAD+ or comparable bioactive markers in biological or reconstructed tissue-based samples, preferably using enzyme-linked immunosorbent assay (ELISA) or another suitable validated analytical method. Experience in cosmetic, dermocosmetic, pharmaceutical, transdermal or bioanalytical testing is a prerequisite. - Stage of Development
- Under development
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 9: Industry, Innovation and Infrastructure
- IPR status
- IPR applied but not yet granted
Partner Sought
- Expected Role of a Partner
-
The partner will act as a specialised testing service provider under a commercial agreement with technical assistance. The selected provider will be expected to propose a suitable experimental setup, define the detailed study protocol in collaboration with the company, carry out the in vitro testing, perform the required quantitative analysis, evaluate the results statistically and prepare a comprehensive final technical report.
Before the cooperation starts, the provider should submit a detailed technical description of the proposed experimental setup, an itemised cost breakdown covering laboratory services, consumables and reporting, an estimated lead time from receipt of samples to final report delivery, and confirmation that the final results can be delivered by 31 October 2026.
Upon project initiation, the selected provider will receive the necessary technical documentation from the company. This will include the qualitative and quantitative product composition, detailed instructions for use and dosage, and the technical data sheets for the raw materials of interest. - Type and Size of Partner
- SME 11-49
- R&D Institution
- SME 50 - 249
- University
- Other
- Big company
- Type of partnership
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 03004011 - Care, Hygiene, Beauty
- 06002007 - In vitro Testing, Trials
- 06002010 - Toxicology
- 06002002 - Cellular and Molecular Biology
- Market keywords
- 07004002 - Health and beauty aids
- 04006 - Cellular and Molecular Biology
- 04009 - In vitro Testing, Trials
- Sector Groups Involved
- Health
- Targeted countries
- All countries